Alle Storys
Folgen
Keine Story von Dr. Hönle AG mehr verpassen.

Dr. Hönle AG

euro adhoc: Dr. Hönle AG
Quarterly or Semiannual Financial Statements
Positive Development at Hönle Continues (E)

  Disclosure announcement transmitted by euro adhoc.
  The issuer is responsible for the content of this announcement.
Hönle, the UV specialist, (ISIN: DE000 515710 1) saw a 35.7 %
increase in sales revenue to TEUR 15.931 in the first nine months of
the 2003/2004 financial year.
Earnings before interest and taxes (EBIT) climbed in the same period
from TEUR 537 (previous year) to TEUR 2,000 and net income for the
period rose from TEUR 1,049 (previous year) to TEUR 1,548. This
represents an EBIT margin of 12.6 % and net profit on sales of 9.7 %.
The equity ratio is 82.6 %. Cash and cash equivalents increased by a
total of TEUR 904 to TEUR 16,538 in the last quarter, this is
equivalent to a cash proportion of EUR 3.16 per share.
Outlook:
Owing to the orders on hand as at 30 June and incoming orders until
the time of reporting, we expect sales revenue of more than EUR 5
million for the fourth quarter of 2004 and a continuation of the
positive trend at Hönle. The DRUPA trade fair brought first positive
revenue effects and gives further reasons for optimism for the coming
quarters.
end of announcement        euro adhoc 13.08.2004

Further inquiry note:

Peter Weinert
Tel.: +49 (0)89 856 08 173
E-Mail: peter.weinert@hoenle.de

Branche: Instrument Engineering
ISIN: DE0005157101
WKN: 515710
Index: CDAX, Prime All Share, Prime Standard, Technologie All Share
Börsen: Frankfurter Wertpapierbörse / regulated dealing
Niedersächsische Börse zu Hannover / free trade
Berliner Wertpapierbörse / free trade
Bayerische Börse / free trade
Hamburger Wertpapierbörse / free trade
Bremer Wertpapierbörse (BWB) / free trade
Börse Düsseldorf / free trade
Baden-Württembergische Wertpapierbörse / free trade

Weitere Storys: Dr. Hönle AG
Weitere Storys: Dr. Hönle AG